vaccine Archives | Page 7 of 8 | Be Korea-savvy
Home / Posts tagged vaccine (Page 7)
Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

GAITHERSBURG, Md., March 11 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Serum Institute of India (SII) today announced a commercial license agreement for the use of Novavax’ proprietary Matrix-M™ vaccine adjuvant with SII’s malaria vaccine candidate. SII licensed the R21 malaria vaccine, which [...]

Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development

Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development

GAITHERSBURG, Md., March 10 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the Coalition for Epidemic Preparedness (CEPI) awarded an initial funding of $4 million to support Novavax’ efforts to develop a COVID-19 vaccine. CEPI and Novavax are having ongoing discussions on [...]

Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) Vaccine

Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) Vaccine

EMERYVILLE, Calif., March 2 (Korea Bizwire) – Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is collaborating with the University of Queensland (UQ) as part of a Coalition for Epidemic Preparedness (CEPI) initiative to develop a vaccine to prevent COVID-19.  Dynavax is providing technical expertise and the Company’s proprietary toll-like receptor [...]

GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute

GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute

LONDON and WASHINGTON, Aug. 6 (Korea Bizwire) — GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently [...]

Batavia Biosciences Receives $2.2 Million Follow-up Grant from PATH to Support New Tools for Polio Eradication Era

Batavia Biosciences Receives $2.2 Million Follow-up Grant from PATH to Support New Tools for Polio Eradication Era

Leiden, Jul. 4 (Korea Bizwire) – Today, Batavia Biosciences announces it received a follow-up grant of $2.2 million from PATH – a global organization dedicated to health equity – to develop and manufacture novel oral poliovirus vaccines (nOPV). The project, which is funded by the Bill & Melinda Gates Foundation, aims to protect children worldwide from all [...]

S. Korean Drug Maker Penalized for Cutting Supply of Free Vaccines

S. Korean Drug Maker Penalized for Cutting Supply of Free Vaccines

SEOUL, May 17 (Korea Bizwire) — A supplier of tuberculosis vaccines for infants was fined and brought to prosecution for cutting the supply of free vaccines in order to sell expensive vaccine products. The Fair Trade Commission fined Korea Vaccine Co. 990 million won (US$830,000) and filed complaints with the prosecution against company staff for [...]

Batavia Biosciences Receives $13.2M Grant to Accelerate Market Access of Low-cost Inactivated Polio Vaccine

Batavia Biosciences Receives $13.2M Grant to Accelerate Market Access of Low-cost Inactivated Polio Vaccine

Leiden, The Netherlands, Feb. 25 (Korea Bizwire) – Batavia Biosciences announced today that it received a $13.2 million grant from the Bill & Melinda Gates Foundation to manufacture clinical-grade inactivated polio vaccine (sIPV), using its newly developed low-cost polio vaccine manufacturing process (marketed as HIP-IPVTM) based on the NevoLine™ manufacturing technology developed by Univercells. In [...]

Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses

Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses

PLYMOUTH MEETING, Pa., Oct. 25 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its synthetic HIV vaccine PENNVAX®-GP delivered via intradermal route demonstrated durable and robust antibody and T cell immune responses measured throughout the duration of the Phase 1 clinical study. In this reported study, PENNVAX-GP plasmids were delivered intradermally or intramuscularly [...]

Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges

Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges

PLYMOUTH MEETING, Pa., Sept. 17 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its SynCon® vaccine approach using a collection of DNA antigens generated broadly protective antibody responses against the most deadly strains of the H3N2 influenza viruses from the past 50 years and provided complete protection against heterologous lethal challenge in a [...]